Biotech Startups

ObjectiveHealth brings clinical trials into local physician practices by integrating technology with electronic health records to identify and match patients to relevant studies. It serves physicians, community health centers, patients, and pharmaceutical sponsors seeking tech-enabled clinical research collaborations.

2 investors

Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.

2 investors

Ohalo develops products aimed at improving agricultural productivity and supporting farmers globally. Founded in 2019, the company works in the agriculture technology and genetics space.

2 investors

Ohmic Biosciences develops engineered proteins and synthetic biology solutions to address diseases in crops. The company creates durable treatments applicable across different agricultural products.

2 investors

Ojer Pharma develops pharmaceutical and cosmetic products for treating skin conditions and infections in human and veterinary markets. The company offers prescription medications, over-the-counter treatments, and dermatological cosmetics addressing conditions ranging from bacterial skin infections to actinic keratosis and herpes simplex.

2 investors

Okomera builds a platform combining miniaturized tumor-on-chip technology and AI imaging to analyze patient-derived biopsies and predict personalized drug response for cancer treatment. Its tools serve clinicians and drug developers, spanning drug development to clinical decision-making.

2 investors

Olfera develops biopharmaceutical treatments for neurological conditions that use the olfactory system as a non-invasive pathway to the brain, bypassing the blood-brain barrier. Its platform is used to discover, optimize, and deliver drugs, converting existing FDA-approved and candidate neurological drugs into easier-to-administer therapies.

2 investors

OliPass develops an antisense oligonucleotide drug-discovery platform based on its chemically modified peptide nucleic acid technology, which improves cell permeability to enable exon-skipping therapeutics. It targets pre-mRNA to generate new drug candidates for therapeutic development.

2 investors

Omanta provides personalized scientific research support for complex disease cases, assigning PhD-level teams to build detailed molecular profiles from a patient's genomic, RNA, and protein data. It cross-references each patient's molecular profile against an internal reference cohort and biomedical literature to model therapeutic options and produce a research roadmap that informs the clinical team's decisions.</parameter> <parameter name="founders">[]

2 investors

Omeat (Evergreen) produces cultivated beef that augments traditional beef supply to deliver price-predictable, consistent-quality product at industrial scale. It partners with ranchers, global meat producers, and beef processors seeking stable pricing and reliable supply without plant-based fillers.

2 investors

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max Delbrück Center for Molecular Medicine in Berlin.

2 investors

Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications. The company pursues orphan, large-market, and novel therapeutic programs through vertically integrated drug development.

2 investors

Vedaly provides AI, data analytics, and decision support tools for biopharma companies to integrate insights into scientific and strategic planning. The platform helps pharmaceutical and biotech teams move faster and make data-driven decisions across drug development and research.

2 investors

Omios Biologics runs a computational drug discovery platform that analyzes viral-host interactions across more than 270 human viruses to identify disease targets and engineer precision therapeutics. Its lead assets are biomarker-driven engineered oncolytic viruses for specific cancer subtypes, with expansion into immune, inflammatory, metabolic, and neurodegenerative diseases.

2 investors

OmniPulse Bio develops next-generation therapies described as pulsatile and programmable. The page provides no concrete detail about the therapeutic area, product, or intended patients.

2 investors

Omniscience.bio builds Vivo, an agentic AI "control tower" that unifies data from clinical trial systems (EDC, CTMS, labs, safety, imaging, eCOA, IRT, documents) into a governed layer where teams ask plain-language questions, monitor risk, and take source-backed action. It serves cross-functional clinical development teams, sponsors, and CRO/FSP partners running active trials, in the clinical trial software and life sciences category.

2 investors

Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.

2 investors

2 investors

Oncimmune is a biomarker discovery and diagnostics company specializing in proteomics and bioinformatics technologies for autoimmunity, cancer research, and clinical drug development. The company serves pharmaceutical, biotech, and academic partners by developing diagnostic tools and biomarkers for various phases of clinical development.

2 investors

OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.

2 investors

Oncodea is a cancer research company developing early cancer detection and monitoring methods intended to be fast, affordable, and accessible to a broad population. It positions itself as more than a research lab, focused on making cancer testing inexpensive enough for regular use.

2 investors

OncoHost develops the PROphet platform, a precision medicine diagnostic tool combining proteomics, bioinformatics, and machine learning to help oncologists predict patient response to cancer therapies and select optimal treatment. The company serves clinicians and cancer patients worldwide with biomarker-driven insights to overcome treatment resistance.

2 investors

First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.

2 investors

OncoInsight develops off-the-shelf natural killer (NK) cell therapy product candidates aimed at treating cancer patients. The company operates in the biotech and cell therapy space.

2 investors